Pediatric neuromuscular disorders: Care considerations during the COVID-19 pandemic

3.1General medical considerations

Given that patients with neuromuscular disease in general have a higher reliance on medical equipment, medications, home care and medical supplies as well as caregiver support, every patient and family should have and review an emergency plan. Supply chains may be affected, home nursing and therapies may be disrupted, and caregivers may be vulnerable to illness or burn out with less community support available. Extra supplies and medications should be secured, and plans should be made for back up caregivers to be trained and available to help if needed. Telehealth appointments should be considered for routine medical appointments if possible. In some instances, telehealth may be a valuable tool to help triage whether an in-person appointment is needed in the event of a non-urgent medical issue.

Patients with neuromuscular disease often have cardiac and respiratory compromise including cardiomyopathy, restrictive lung disease, impaired cough function, aspiration, and sleep-disordered breathing. They may rely on medical technology (non-invasive or invasive ventilation, mechanical in-exsufflation, suction, inhaled medications, etc.) to maintain respiratory health[13, 14]. Patients with acute cardiorespiratory symptoms, fever, or increased respiratory secretions, thought secondary to COVID-19 or another viral illness, should be evaluated in a health care facility capable of managing their complex condition. If this is not possible, the evaluating provider should contact the patient’s neuromuscular team for assistance and to discuss the respiratory care plan. The patient and caregivers should bring their home equipment and settings to any urgent or scheduled visit to eliminate treatment lag time in set up and fitting equipment and accessories.

Initial evaluation should include vital signs and a complete physical examination including thorough cardiorespiratory exam. Diagnostic testing should include chest X-ray, blood gas, and evaluation of electrolytes and renal function. Of note, renal function is often overestimated by serum creatinine values in patients with muscle disease. Therefore, a careful assessment of fluid status is needed, and providers should consider non-routine renal function tests such as cystatin C. In patients with cardiac disease, an electrocardiogram (ECG) should be obtained. Patients with neuromuscular disease, especially SMA, are at risk for hypoglycemia during prolonged fasting. Therefore, measurement of serum glucose and initiation of a supportive glucose infusion rate is recommended.

3.2Respiratory care

Patients with neuromuscular disease can have a range of respiratory function, from normal to severe restriction and chronic respiratory failure. COVID-19 risk stratification by baseline lung function parameters or other functional parameters has not been established. However, those patients with a forced vital capacity less than 50% predicted, impaired cough function, or established use of noninvasive ventilation or augmented airway clearance, should be considered most at risk for acute respiratory failure, intubation, and death from any respiratory tract infection[13, 15]. Patients with mild-to-moderate restrictive lung disease (FVC % predicted > 50% and less than 80%) or with moderately diminished cough function should also be considered at risk for severe respiratory disease as respiratory muscle load is increased during times of physiologic stress and can result in rapid deterioration[13, 14]. Patients with episodic or waxing/waning diseases like some congenital myasthenic syndromes and myasthenia gravis may have normal lung function when well but can have profound changes in respiratory muscle function in response to respiratory infections[16].

Assessing risk of respiratory failure in infants and children too young or too impaired to perform pulmonary function tests is challenging. Underlying diagnosis (including but not limited to spinal muscular atrophy types 1 and 2, congenital myotonic dystrophy, severe congenital myopathies, severe congenital muscular dystrophies, and mitochondrial myopathies) can imply high risk of acute respiratory failure[17]. Prior use of noninvasive ventilation, sleep-disordered breathing at baseline, impaired cough function, use of augmented cough devices at baseline, a history of respiratory failure or hospitalization with respiratory infections, or prolonged intubation after anesthesia are historical clues that should prompt aggressive interventions with noninvasive ventilation and augmented cough function. Whenever possible, consultation with the patient’s neuromuscular team, especially the pulmonologist and respiratory therapist, is advised.

Respiratory care should focus on airway clearance and assistive ventilation. Biphasic noninvasive ventilation to support respiratory effort and airway clearance aimed at augmenting cough function are the mainstays of respiratory support and should be used early in acute disease[13, 14, 18, 19]. In children and adults with neuromuscular disease, hypoxemia is often a sign of hypoventilation. Patients may not display respiratory distress because of weak respiratory muscles. Therefore, a high index of suspicion is required to assess patients adequately.

In patients with known restrictive lung disease (FVC < 80% predicted), inspiratory muscle weakness (maximal inspiratory pressure < 60 cm H2O), chronic hypoventilation, or sleep-disordered breathing, biphasic noninvasive ventilation should be used early in illness[13, 14]. This modality should be used even in the absence of acute hypoventilation on blood gas analysis in order to support respiratory muscle function and reduce the risk of acute respiratory failure caused by increased respiratory muscle load and metabolic demand. Supplemental oxygen, high flow nasal cannula oxygen, and continuous positive airway pressure (CPAP) are not appropriate treatments for patients with neuromuscular disease [13, 14]. Patients with previously normal lung function should be evaluated carefully as acute illness can exacerbate muscle weakness and lead to acute respiratory failure. Supplemental oxygen may be used in conjunction with biphasic noninvasive ventilation once adequate ventilation is achieved. Increases in the fraction of inspired oxygen (FiO2) suggest mucus obstruction, atelectasis, worsening lower respiratory tract disease, or worsening hypoventilation. Therefore, providers should consider adjustment of noninvasive ventilation settings to address hypoxemia.

In some cases, intubation with mechanical ventilation is indicated. Medical providers should discuss this with patients or their families as many have advance directives. The primary neuromuscular team that knows the patient well should be involved in this discussion when possible. While an acute illness such as COVID-19 may be treatable with invasive mechanical support, the underlying neuromuscular condition may not permit extubation after a significant illness and so the team should discuss the possibility of tracheostomy.

Airway clearance should focus on augmenting impaired cough function[13, 14, 17, 18, 19]. In adolescents and adults, a peak cough flow less than 160 L/min when well is associated with impaired mucus clearance[15]. A peak cough flow between 160 and 270 L/min is associated with increased risk of impaired cough function during illness and these patients should receive aggressive airway clearance[20]. Normative data for peak cough flows do not exist in younger children. Historical signs of impaired cough function should be investigated. Mechanical augmentation of cough function is usually achieved with mechanical in-exsufflation, commonly referred to as cough assist. This device can be used with a variety of interfaces including mouthpiece, facemask, and endotracheal tube. Hypoxemia is often a result of mucus obstruction and should be treated with aggressive airway clearance. An experienced pulmonologist or respiratory therapist is vital to achieving best results. Mechanical in-exsufflation can also prevent failures of extubation[21]. Airway clearance is sometimes augmented with inhaled medications (bronchodilators or mucolytics)[22, 23] or other mechanical treatment such as a vibration vest [24, 25] or intrapulmonary percussive ventilation[26, 27]. These may be added to mechanical in-exsufflation and noninvasive ventilation on an as needed basis but are not sufficient alone[13, 14, 18, 19].

Because SARS-CoV-2, the virus that causes COVID-19 disease, is spread by airborne droplets [2, 3] and invasive and noninvasive ventilation and mechanical airway clearance are thought to increase the possibility of generating infectious droplets, some healthcare facilities have attempted to limit the use of these therapies. This is not appropriate for patients with neuromuscular disorders and can lead to prolonged respiratory illness, more severe illness, and death. Neuromuscular advocacy groups have made recommendations and many healthcare facilities have adjusted their practice by utilizing various strategies such as filters, personal protective equipment (PPE), and isolation practices to permit these respiratory therapies while reducing risk of aerosolization contamination33 Patients and parents should advocate for these practices.

3.3Acute management considerations for patients on steroids

Daily glucocorticoid therapy remains the mainstay of treatment for DMD to improve and prolong muscle strength and cardiac and pulmonary function[28, 29]. Steroid treatment is indicated in all stages of the disease and thus often prescribed for many years, spanning a patient’s life, decades from the time of initial prescription[30]. Additionally, glucocorticoid therapy may be trialed in a variety of other neuromuscular diagnoses [31]. Patients receiving onasemnogene aboparvovec gene transfer therapy for SMA are treated with oral prednisolone one day prior to dosing and for at least two months after treatment. Treatment with chronic systemic steroids, however, is known to cause significant multi-system side effects, including but not limited to, suppression of endogenous adrenal function with subsequent adrenal insufficiency and immunosuppression[32, 33]. As such, the Center for Disease Control and Prevention (CDC) currently lists individuals on chronic corticosteroid therapy as one of a number of high risk groups for the development of severe disease from COVID-19 infections. However, the immediate discontinuation of chronic steroid therapy is not a feasible option for most individuals due to ongoing benefits of therapy and risk for sequela of stopping after chronic use.[29, 34]. Therefore, important considerations must be made in guiding ongoing corticosteroid therapy in patients with neuromuscular disease with or without active SARS-CoV-2 infection[30, 35].

Many organizations, including the CDC, the Endocrine Society, the Muscular Dystrophy Association, and Parent Project Muscular Dystrophy, advise patients with neuromuscular conditions treated with chronic steroid therapy to not abruptly cease their regular medications[30, 35]. Discontinuation of therapy may precipitate an adrenal crisis, a life-threatening medical emergency due to deficiency of cortisol, the body’s endogenous glucocorticoid, in the absence of exogenous steroids[34]. The PJ Nicholoff Steroid Protocol was developed specifically to address such concerns in males with Duchenne and Becker muscular dystrophy[30]. Adrenal crises in patients with suppressed adrenal function typically occurs in the setting of physiologic stressors such as a febrile illness, which is likely to be seen with COVID-19 infections[32]. Patients with neuromuscular conditions receiving chronic glucocorticoid therapy should be taught stress dose precautions including when and how to increase their steroids as well as how to administer an intramuscular injection of hydrocortisone (Solucortef®) to mitigate the risk of decompensation in the setting of COVID-19 should they become ill[34]. Both the current clinical care guidelines for the management of DMD and the PJ Nicholoff Steroid Protocol detail typical dosing strategies[29, 30]. If hospitalized due to severe illness, patients’ home steroids should be converted to hydrocortisone to cover their stress dose needs and to reduce the risk of adverse outcomes of high dose corticosteroid therapy, although data in pediatric patients with COVID-19 are lacking[36]. Consultation with a pediatric endocrinologist should be considered[35].

3.4Issues around receiving novel treatments for SMA and DMD during a pandemic

For those living with neuromuscular conditions, the treatment landscape is changing with many novel therapies in clinical trial and some receiving FDA approval[37, 38]. For providers delivering care to individuals being treated with one of these approved drugs, it is important to be familiar with the dosing schedules, potential challenges if doses are missed, and considerations for resuming treatments that may be put on hold. Planning for these instances will improve care delivery.

Exon skipping drugs including eteplirsen and golod-irsen[39, 40] used to treat boys with DMD are given as weekly intravenous infusions either in the hospital, infusion center, or at home in most circumstances. Individual cases should be reviewed to determine the safest scenario for patients and their families to limit exposure to SARS-CoV-2. For home therapy, there should be systems in place whereby home health providers are screened and supplied with appropriate PPE prior to giving infusions. To further limit exposure and excess patient clinic visits, safety labs can be drawn by home health providers as well.

Patients with SMA currently have two FDA approved therapies available[41]. Onasemnogene abeparvovec (gene transfer therapy) is approved for children under the age of two years and nusinersen is for patients of all ages with 5q SMA. Both of these treatments require administration at a health care facility. Depending on the facility, SARS-CoV-2 testing prior to any treatment or procedure may be required. Especially for newly diagnosed patients, there is urgency to initiate treatment quickly as several studies have shown that earlier treatment leads to improved outcomes[42, 43]. Many states now have newborn screening programs in place resulting in identification of presymptomatic infants who may derive significant benefit if treated in the first weeks of life. Treatment with either of these agents is critical to the health of patients with SMA and should not be considered optional or elective and thus subject to delays.

Onasemnogene abeparvovec is administered through a peripheral IV. Patients are treated with oral prednisolone one day prior to dosing and for at least two months after treatment. They need close clinical and laboratory follow up for thrombocytopenia, troponin and elevated liver enzymes during this period of time. Throughout the period of immunosuppression, family members and care providers should closely follow recommended COVID-19 guidelines regarding hand washing and social distancing measures. Consideration should be given to use of telehealth appointments when appropriate as well as home health visits for laboratory assessments. As stated earlier, appropriate PPE and COVID-19 safeguards must be in place for any home health monitors.

Nusinersen is delivered via intrathecal injection. Four loading doses are given during the first two months of treatment and quarterly thereafter for life. Lumbar punctures may be done in an office, procedure center, or an interventional radiology suite depending on the patient’s clinical status and degree of spinal deformity. Anesthesia for the procedure may be required which increases risk for both the patient and medical team. If a dose is missed or delayed, nusinersen package insert instructions advise treating as quickly as possible to maintain appropriate cerebrospinal fluid concentration. Safety labs for coagulopathies and urine protein are monitored prior to dosing.

4.1Telehealth utilization for clinical assessments

Regular assessments, typically every 6 months, of patients with neuromuscular conditions such as spinal muscular atrophy and Duchenne muscular dystrophy are recommended for most neuromuscular diagnosis. Telerehabilitation can give providers the opportunity to observe the patients in their natural environment and in many cases provides a window into the resources as well as limitations to patient’s care at home. Outcome measurement assessments administered by telerehabilitation cannot be done in the standardized manner in which they were designed in most cases. Modified versions of these assessments, however, can be done by using a little creativity and can provide useful information on current status and help in making recommendations for therapy interventions. For example, many household items such as quarters, plastic containers with lids, printer paper, and soup cans can be used to substitute for standardized items in the Performance of Upper Limb [45] used for patients with Duchenne/Becker muscular dystrophy and the Revised Upper Limb Module[46], used for patients with SMA. The Northstar Ambulatory assessment (NSAA)[47], is a useful tool for measuring ambulatory function in Duchenne and many other neuromuscular diagnoses. Most of the items in this assessment can easily be administered during a telehealth visit with some exceptions and modifications. Similarly, many items on the CHOP INTEND[48], Hammersmith Functional Motor Scale Expanded (HFMSE) [49] and Revised Hammersmith scale (RHS) [50] can also be done with some limitations and modifications via telehealth. Accurate comparisons to past testing results are not possible and a statement to that effect should be noted in the medical record. Timed function testing cannot be done due to time delays on video and range of motion measurements cannot be accurately administered via telehealth. However, useful information on current function can be obtained from these modified assessments and can help guide home therapy and exercise recommendations.

It is important to note that because assessments cannot be accurately compared to previous assessments, they cannot be used for clinical trial exams. International academic networks are currently working to develop, standardize and validate telehealth (telerehabilitation) assessments.

Additionally, prior to authorizing approval or re-approval for reimbursement for novel treatments such as eteplirsen, golodirsen, or nusinersen, many insurance companies require standardized testing. Care providers may need to proactively discuss these challenges with payors. Functional assessments required in clinical trials will vary depending on the sponsor, local or central IRB requirements, and the hospital in which they are performed. Research therapists should work closely with the Principal Investigator and Research Coordinator to assure adherence to the study protocol in the setting of the pandemic.

Adaptive equipment management can be performed with some limitations if an in-person visit is not possible. In other cases, equipment that is not typically available for in-clinic visits can be evaluated via telehealth. This is a great way to assess fit, proper use and safety of home equipment. Standers, walkers, sitting devices, backup wheelchairs or power chairs that can’t be transported can be seen for perhaps the first time. Families can be encouraged to share their creative home “inventions” both for function and recreation thereby providing caregivers and therapists an opportunity to learn and share with others. Durable medical equipment providers may be available for in-person visits or telehealth to make necessary repairs or to assist with the face-to-face assessments that are often required. Providers and therapists should collaborate with them to address patient needs as quickly as possible.

Orthotics should be assessed for fit during each visit whether in person or by telehealth. If any pressure areas are detected, the patient should be directed to contact their orthotist. If modifications cannot be made due to visitation restrictions, avoiding use should be advised until these modifications can be done.

4.2Home exercise and therapy program considerations

Providing therapy is typically hands-on and finding ways to make this work remotely can dramatically change the way it is performed. However, integrating therapy into virtual visits is possible and can be quite helpful. Telerehabilitation may be provided by community, school or clinic therapists. Scheduling telehealth therapy visits should be coordinated with the multiple other virtual appointments a child may have with online learning, IEP meetings and visits with medical providers. The therapist providing care remotely takes on more of a teaching rather than touching role and has the responsibility to guide the parents in the activities that are recommended. Coordinating and sharing goals between therapists is essential for continuity of care and to create shared goals. Setting expectations appropriately while keeping in mind the limitations and stress the caregivers might be experiencing is important to consider.

Continued use of night splints, standers and daily stretching and positioning should be recommended for most patients especially if the child is receiving more limited therapy services[51] and may be more helpful if incorporated into a daily routine[51]. During the COVID-19 pandemic, the parent or caregiver has been forced to assume the sole responsibility for providing all the in-person therapy services that were previously provided by the therapists.

Encouraging physical activity during the pandemic is recommended as it is useful in preventing disuse atrophy and contractures [29, 44]. Creative suggestions are needed when social distancing guidelines are in place and may include: a walk around the block, a family bike ride, use of a stander while playing a game, hand or leg ergometers, massage, dance parties, virtual yoga or Pilates, pool therapy in the bathtub, bubbles or even meditation for deep breathing.

In summary, rehabilitation assessments and therapy interventions can and should be modified through telerehabilitation and telephone encounters when in-person visits are not possible. Individualized plans of care should be developed to meet the needs and challenges of each patient.